Efficient and Effective Early Stage Breast Cancer Treatment
World's first SBRT device designed to treat breast cancer in 1-5 fractions with less side effects.
XCISION MEDICAL SYSTEMS, LLC
Xcision’s initial focus is on breast cancer, using stereotactic partial breast irradiation to treat patients eligible for breast conserving therapy. The company’s first product, GammaPod™, is a new stereotactic radiotherapy system optimized for the treatment of breast cancer in one to five sessions. The system has been developed based on a patent from the University of Maryland.
Columbia, Maryland (MD), United States
Healthcare
About
Xcision Medical Systems, LLC is a medical technology company developing advanced stereotactic radiotherapy solutions with the potential to significantly improve the quality of cancer care as well as the lives of patients and their loved ones. The company’s technology is designed to extend the benefits of radiation oncology to more patients and enable precision noninvasive treatments that allow patients to return to living fuller lives more quickly with less discomfort after receiving a cancer diagnosis.
Xcision’s initial focus is on breast cancer, using stereotactic radiotherapy to deliver focused radiation to a partial volume of the breast in conjunction with breast conserving treatment. The company’s first product, GammaPod™, is a new stereotactic radiotherapy system optimized for the treatment of breast cancer. The delivery of higher doses in one or several large fractions differentiates stereotactic radiotherapy from conventional techniques. The system has been developed based on a patent licensed from the University of Maryland School of Medicine.
Xcision’s initial focus is on breast cancer, using stereotactic radiotherapy to deliver focused radiation to a partial volume of the breast in conjunction with breast conserving treatment. The company’s first product, GammaPod™, is a new stereotactic radiotherapy system optimized for the treatment of breast cancer. The delivery of higher doses in one or several large fractions differentiates stereotactic radiotherapy from conventional techniques. The system has been developed based on a patent licensed from the University of Maryland School of Medicine.
